Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
10
RSLS Quote, Financials, Valuation and Earnings
Last price:
$2.52
Seasonality move
:
-37.13%
Day range:
$2.41 - $2.74
52-week range:
$2.23 - $415.00
Dividend yield:
0%
P/E ratio:
0.01x
P/S ratio:
0.01x
P/B ratio:
1.51x
Volume:
1.2M
Avg. volume:
5M
1-year change:
-99.15%
Market cap:
$1.9M
Revenue:
$8M
EPS (TTM):
$262.50
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Reshape Lifesciences has 57439.61% upside to fair value with a price target of -- per share.
RSLS vs. S&P 500
-
Over the past 5 trading days, Reshape Lifesciences has underperformed the S&P 500 by -39.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Reshape Lifesciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Reshape Lifesciences revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Reshape Lifesciences reported revenues of $1.1M.
Earnings Growth
-
Reshape Lifesciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Reshape Lifesciences reported earnings per share of $474.50.
Enterprise value:
-654.5K
EV / Invested capital:
-0.53x
Price / LTM sales:
0.01x
EV / EBIT:
--
EV / Revenue:
-0.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.6M
Return On Assets:
-54.94%
Net Income Margin (TTM):
-48.27%
Return On Equity:
-172.58%
Return On Invested Capital:
-159.67%
Operating Margin:
-165.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $11.1M | $8.3M | $7.2M | $1.9M | $1.1M | |
| Gross Profit | $6.8M | $5.5M | $4.6M | $1.2M | $681K | |
| Operating Income | -$24.6M | -$11.2M | -$6.3M | -$2.2M | -$1.8M | |
| EBITDA | -$22.9M | -$11.1M | -$6.3M | -$2.2M | -$1.8M | |
| Diluted EPS | -$122,425.85 | -$3,290.33 | $262.50 | -$135.37 | $474.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.3M | $23.6M | $15.2M | $7.9M | $6.3M | |
| Total Assets | $36M | $47.3M | $16.4M | $8.2M | $6.5M | |
| Current Liabilities | $21.6M | $8.2M | $7.6M | $3.5M | $4.1M | |
| Total Liabilities | $23.3M | $8.6M | $8.6M | $3.7M | $5.3M | |
| Total Equity | $12.7M | $38.6M | $7.8M | $4.5M | $1.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.6M | -$14M | -$4.5M | -$2.1M | -$2.1M | |
| Cash From Investing | -$101K | -$3K | -- | -- | -- | |
| Cash From Financing | $13.3M | $7.4M | $4.6M | -- | $3.9M | |
| Free Cash Flow | -$19.7M | -$14M | -$4.5M | -$2.1M | -$2.1M | |
RSLS
Sector
Market Cap
$1.9M
$33.4M
Price % of 52-Week High
0.61%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
181.16%
-0.6%
1-Year Price Total Return
-99.15%
-37.4%
Beta (5-Year)
1.284
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.28
200-day SMA
Sell
Level
$86.87
Bollinger Bands (100)
Sell
Level
-4.31 - 56.23
Chaikin Money Flow
Sell
Level
-61M
20-day SMA
Sell
Level
$4.48
Relative Strength Index (RSI14)
Sell
Level
35.93
ADX Line
Buy
Level
21.67
Williams %R
Buy
Level
-95.2145
50-day SMA
Sell
Level
$7.28
MACD (12, 26)
Sell
Level
-1.59
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
159M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-190.362)
Sell
CA Score
(Annual)
Level (-4.3394)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (11.4322)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Stock Forecast FAQ
In the current month, RSLS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RSLS average analyst price target in the past 3 months is --.
-
Where Will Reshape Lifesciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Reshape Lifesciences share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Reshape Lifesciences?
Analysts are divided on their view about Reshape Lifesciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Reshape Lifesciences is a Sell and believe this share price will drop from its current level to --.
-
What Is Reshape Lifesciences's Price Target?
The price target for Reshape Lifesciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RSLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Reshape Lifesciences is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RSLS?
You can purchase shares of Reshape Lifesciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Reshape Lifesciences shares.
-
What Is The Reshape Lifesciences Share Price Today?
Reshape Lifesciences was last trading at $2.52 per share. This represents the most recent stock quote for Reshape Lifesciences. Yesterday, Reshape Lifesciences closed at $2.52 per share.
-
How To Buy Reshape Lifesciences Stock Online?
In order to purchase Reshape Lifesciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
